Optimizing Biomarker-Driven Management in NSCLC: Focus on STK11, MTAP, TROP2, EGFR, KRAS, and MET

Discover why combining tissue NGS, ctDNA and IHC uncovers actionable NSCLC biomarkers, shaping first-line therapy, resistance, and new ADC options.

Experts explain combining tissue NGS, ctDNA liquid biopsy and IHC to uncover actionable NSCLC biomarkers and guide first-line targeted therapy.

Experts unpack NGS, ctDNA and protein testing to speed actionable biomarker detection and guide targeted therapy choices in advanced lung cancer.

See how KRAS mutations, especially G12C, guide NSCLC treatment sequencing—from PD-L1 strategy to sotorasib/adagrasib and emerging trials.

Learn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.

Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.

How Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.

Decode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.

Explore NSCLC precision oncology gaps: expand targets beyond EGFR, refine liquid biopsies and MRD, and fix incomplete NGS testing.

Learn why paired tissue and liquid NGS at diagnosis and progression uncovers actionable NSCLC alterations, guiding trials and future monitoring.